Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:[1]

Kissei Pharmaceutical
ISINJP3240600001
IndustryPharmaceutical products, therapeutic and care foods
FoundedAugust 9, 1946; 78 years ago (1946-08-09)
Headquarters,
Japan
Key people
Mutsuo Kanzawa (CEO)
Number of employees
1504
Websitewww.kissei.co.jp/e_contents/

In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.[2]

References

edit
  1. ^ "English Home".
  2. ^ "CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries". www.businesswire.com. 2020-03-27. Retrieved 2020-06-04.